{
  "markdown": "# Principles of Neoplasia: A Molecular and Clinical Comprehensive\n\n## 1. Fundamental Tumor Biology: Monoclonality and Classification\n\nThe shift from normal cellular homeostasis to neoplastic growth represents a catastrophic failure of the deterministic signals governing tissue architecture and cellular proliferation. In the physiological state, cell cycle control is maintained by a complex regulatory network; however, neoplasia arises when the enabling characteristic of Genome Instability and Mutation permits the bypass of these constraints (Hanahan & Weinberg, 2011; Hanahan, 2022). Understanding the monoclonal origin of tumors-the fact that a malignancy commences with the transformation of a single progenitor-is essential for targeted therapeutic interventions. This clonal foundation dictates that while a tumor may become highly heterogeneous through subclonal evolution, its constituent cells share a common lineage, providing the molecular handprints necessary for precise diagnostic and therapeutic targeting.\n\n### Nomenclature and Origin\n\nTumor nomenclature is fundamentally bifurcated by biological behavior into benign and malignant. Benign tumors are generally localized, whereas malignant neoplasms (cancers) are pathologically distinguished by their capacity to breach the basement membrane and destroy surrounding architecture. Central to this process is monoclonality. Neoplasms originate from the transformation of a single cell that acquires a selective growth advantage. As this cell divides, it gives rise to a genetically heterogeneous but clonally related population. Over time, selective pressures-including immune surveillance and therapeutic intervention-sculpt this population, yet the shareable monoclonal origin remains the defining hallmark of the tumor's identity (Pierantoni et al., 2024; van Zijl et al., 2011).\n\n### Comparative Analysis of Neoplasms\n\n| Criteria | Benign Neoplasms | Malignant Neoplasms |\n| --- | --- | --- |\n| Differentiation / Anaplasia | Well-differentiated; resembles tissue of origin. | Ranges from well-differentiated to anaplastic. |\n| Rate of Growth | Usually slow; may stop or regress. | Typically rapid; erratic or autonomous. |\n| Boundary | Circumscribed or encapsulated. | Irregular; infiltrative. |\n| Local Invasion | Does not invade; remains localized. | Infiltrative and destructive to basement membrane. |\n| Metastasis | Absent. | Frequently present; the defining lethal trait. |\n\n### Clinical Significance of Biological Divergence\n\nThe biological divergence between benign and malignant tumors dictates the selection of treatment modalities. Benign tumors often allow for watchful waiting or simple surgical excision due to their circumscribed nature. In contrast, the infiltrative and metastatic capacity of malignant tumors necessitates aggressive, multi-modal management. The choice between local control (surgery, radiotherapy) and systemic intervention (chemotherapy, immunotherapy) is governed by the risk of subclinical dissemination, which remains the primary driver of cancer-related mortality (van Zijl et al., 2011).\n\nWhile classification provides the \"what\" of a tumor, the mechanistic \"how\" is determined by the specific genetic and epigenetic drivers that fuel the transition from homeostasis to malignancy.\n\n---\n\n## 2. Carcinogenesis: The Molecular Logic of Transformation\n\nCarcinogenesis is governed by the Multistep Mutation Theory, which posits that the transition from a benign polyp to an invasive carcinoma is a cumulative process of genetic and epigenetic insults. In colorectal cancer (CRC), this is visualized as a predictable progression where each hit confers a selective phenotypic advantage. This transition is not merely about growth; it is about the systematic dismantling of cellular checks and balances (Pierantoni et al., 2024).\n\n### Genetic Drivers of Transformation\n\n- Oncogenes: These genes sustain proliferative signaling. Mutations in KRAS or BRAF trigger the Ras/MAPK cascade. Crucially, this involves signaling through RAF, PI3K, MAPK, and RALGDS, which collectively drive autonomous growth and resistance to apoptosis (Pierantoni et al., 2024).\n- Tumor Suppressor Genes: The \"Two-Hit\" hypothesis typically governs these loss-of-function events. In the Chromosomal Instability (CIN) pathway, the loss of APC is a hallmark. Mechanistically, APC mutation causes a reduction in beta-catenin degradation, allowing beta-catenin to accumulate and translocate to the nucleus, where it activates pro-proliferative gene programs. Subsequent loss of TP53 eliminates the cell's ability to trigger senescence or apoptosis in response to DNA damage (Pierantoni et al., 2024).\n- DNA Repair Genes: The Microsatellite Instability (MSI) pathway arises from a defective DNA mismatch repair (MMR) system, often via the silencing of MLH1 or MSH2.\n\n### Clinical Impact: The \"So What?\" Layer\n\nThe molecular pathway of a tumor dictates its clinical management. CIN-driven tumors are characterized by gross structural anomalies, while MSI-H (MSI-High) tumors exhibit a high mutational load. This high mutational burden is clinically significant because it results in the production of numerous neoantigens. These neoantigens make MSI-H tumors highly susceptible to PD-1 inhibition (e.g., pembrolizumab), as the immune system can more readily recognize the \"non-self\" nature of the tumor (Pierantoni et al., 2024; Hanahan, 2022).\n\nThese genetic alterations confer the phenotypic plasticity required for the tumor to survive in hostile environments and adopt new identities during progression.\n\n---\n\n## 3. Phenotypic Plasticity and the Hallmarks of Cancer\n\nA revolutionary dimension of the Hallmarks of Cancer is Phenotypic Plasticity, which describes the ability of cancer cells to escape terminal differentiation and adopt progenitor-like states. Crucially, this plasticity often occurs independently of genetic mutation, relying instead on nonmutational epigenetic reprogramming to alter cellular identity (Hanahan, 2022; CST Blog, 2022).\n\n### Mechanisms of Plasticity\n\n- Dedifferentiation: Mature cells revert to a progenitor state. A primary model is the Epithelial-Mesenchymal Transition (EMT), where epithelial cells lose apical-basal polarity and adopt a motile phenotype. This is driven by the \"Cadherin Switch\" (loss of E-cadherin, gain of N-cadherin) and a network of transcription factors: Snail, Slug, ZEB1, and Twist (CST Blog, 2022).\n- Blocked Differentiation: Progenitor cells are prevented from reaching a post-proliferative state. In Acute Myeloid Leukemia (AML), cells retain high proliferative capacity. Pathologists investigate these blocked progenitors using specific biomarkers: CD33 and Myeloperoxidase (MPO) (CST Blog, 2022).\n- Transdifferentiation: Cells transform into a different differentiated lineage. In Barrett's Esophagus, squamous cells transform into intestinal-like columnar cells. This is confirmed by the presence of intestinal markers (CDX2, MUC2) and a shift in keratins (CK7/CK20) (CST Blog, 2022).\n\n### Clinical Strategy: Differentiation Therapy\n\nUnderstanding \"Blocked Differentiation\" has permitted the development of Differentiation Therapy. In Acute Promyelocytic Leukemia (APL), chromosomal translocations disrupt retinoic acid (RA) signaling, halting myeloid maturation. By pharmacologically restoring RA signaling, clinicians can force leukemic cells to complete their differentiation into post-proliferative states, effectively inducing remission without cytotoxic destruction (CST Blog, 2022).\n\nThis cellular agility is the prerequisite for the physical act of invasion and the navigation of the lethal metastatic cascade.\n\n---\n\n## 4. Mechanisms of Tumor Progression: Invasion and the Metastatic Cascade\n\nThe Metastatic Cascade is a multi-step process that is statistically inefficient-fewer than 0.1% of disseminated cells successfully colonize-yet it remains the primary cause of cancer death. To succeed, tumor cells must overcome physical, physiological, and immunological barriers (van Zijl et al., 2011).\n\n### Modes of Invasion and Movement\n\n- Collective Invasion: Cells move as coordinated clusters. Leading \"tip cells\" drive the process through focal adhesions and ECM rearrangement.\n- Mesenchymal-to-Amoeboid Transition (MAT): Mesenchymal movement is protease-dependent and slow. However, when proteases are inhibited, cells switch to Amoeboid movement-a high-velocity, protease-independent strategy where cells squeeze through ECM gaps. This transition is regulated by EphA2 kinase, p27 kip1, and p53 (van Zijl et al., 2011).\n\n### Molecular Mechanism of Intravasation\n\nTumor cells actively create \"gates\" for transmigration. Mammary carcinoma cells use ALOX12/15 to metabolize arachidonic acid into 12(S)-HETE. This metabolite transiently reduces VE-cadherin expression in endothelial cells, creating circular defects through which the tumor cells can enter the vasculature (van Zijl et al., 2011).\n\n### The Role of the Microenvironment\n\nTumor progression is a heterotypic process. Cancer-Associated Fibroblasts (CAFs) communicate with cancer cells via a CXCL12/CXCR4 loop, facilitating migration. Simultaneously, Integrins (e.g., \\alpha V\\beta 3) localize Matrix Metalloproteinases (MMPs) to the leading edge to degrade the ECM (van Zijl et al., 2011; Koistinen & Heino, 2000-2013). The clinical failure of MMP inhibitors is largely due to the MAT exit strategy, highlighting the need for multi-modal therapy.\n\n---\n\n## 5. Clinical Evaluation: Grading, Staging, and Screening Principles\n\nPathological grading and clinical staging translate molecular complexity into a standardized roadmap for management. While grading assesses the tumor's \"personality,\" staging determines its \"territory.\"\n\n### Grading and Staging Defined\n\n- Grading: A measure of cytological differentiation (e.g., the Gleason score).\n- Staging: Defined by the TNM System (Tumor size, Node involvement, Metastasis).\n\n### Metastatic Models: Linear vs. Parallel\n\nThe Linear Progression Model suggests dissemination occurs late, after the primary tumor has extensively evolved. Conversely, the Parallel Progression Model claims early dissemination. A classic example of the latter is ERBB2 (HER2/neu) mutant breast cancer, where dissemination often occurs prior to morphological invasion of the primary tumor (van Zijl et al., 2011).\n\n### The \"Seed and Soil\" Theory: Mechanistic \"Why\"\n\nStephen Paget's theory explains organ-specific metastasis. For instance, breast cancer preferentially colonizes bone because the bone matrix stores TGF-beta. When tumor cells invade, the release of TGF-beta stimulates the production of parathyroid hormone-related protein and RANKL, which mobilizes osteoclasts. This creates an osteolytic cycle that provides a fertile environment for tumor growth (van Zijl et al., 2011). This mechanistic understanding dictates that screening must be targeted toward the specific \"soils\" most compatible with a given \"seed.\"\n\nThe future of oncology lies in merging these established clinical frameworks with the molecular pathways of phenotypic plasticity and genetic instability to create a personalized approach to care.\n\n---\n\n## 6. Works Cited\n\n1. Cell Signaling Technology. (2022). Hallmarks of cancer: Unlocking phenotypic plasticity - CST blog. https://www.cellsignal.com/blog/hallmarks-of-cancer-unlocking-phenotypic-plasticity\n2. Hanahan, D. (2022). Hallmarks of cancer: New dimensions. Cancer Discovery, 12(1), 31-46. https://doi.org/10.1158/2159-8290.CD-21-1059\n3. Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. Cell, 144(5), 646-674. https://doi.org/10.1016/j.cell.2011.02.013\n4. Koistinen, P., & Heino, J. (2000-2013). Integrins in cancer cell invasion. Madame Curie Bioscience Database. Landes Bioscience. https://www.ncbi.nlm.nih.gov/books/NBK6070/\n5. Pierantoni, C., Cosentino, L., & Ricciardiello, L. (2024). Molecular pathways of colorectal cancer development: Mechanisms of action and evolution of main systemic therapy compounds. Digestive Diseases, 42(4), 319-324. https://doi.org/10.1159/000538511\n6. van Zijl, F., Krupitza, G., & Mikulits, W. (2011). Initial steps of metastasis: Cell invasion and endothelial transmigration. Mutation Research, 728(1-2), 23-34. https://doi.org/10.1016/j.mrrev.2011.05.002",
  "boxes": [
    {
      "title": "Principles of Neoplasia: A Molecular and Clinical Comprehensive",
      "body_markdown": ""
    },
    {
      "title": "1. Fundamental Tumor Biology: Monoclonality and Classification",
      "body_markdown": ""
    },
    {
      "title": "Genome Instability and Mutation",
      "body_markdown": "The shift from normal cellular homeostasis to neoplastic growth represents a catastrophic failure of the deterministic signals governing tissue architecture and cellular proliferation. In the physiological state, cell cycle control is maintained by a complex regulatory network; however, neoplasia arises when the enabling characteristic of  permits the bypass of these constraints (Hanahan & Weinberg, 2011; Hanahan, 2022). Understanding the monoclonal origin of tumors—the fact that a malignancy commences with the transformation of a single progenitor—is essential for targeted therapeutic interventions. This clonal foundation dictates that while a tumor may become highly heterogeneous through subclonal evolution, its constituent cells share a common lineage, providing the molecular handprints necessary for precise diagnostic and therapeutic targeting."
    },
    {
      "title": "Nomenclature and Originbenignmalignantmonoclonality",
      "body_markdown": "Tumor nomenclature is fundamentally bifurcated by biological behavior into  and . Benign tumors are generally localized, whereas malignant neoplasms (cancers) are pathologically distinguished by their capacity to breach the basement membrane and destroy surrounding architecture. Central to this process is . Neoplasms originate from the transformation of a single cell that acquires a selective growth advantage. As this cell divides, it gives rise to a genetically heterogeneous but clonally related population. Over time, selective pressures—including immune surveillance and therapeutic intervention—sculpt this population, yet the shareable monoclonal origin remains the defining hallmark of the tumor's identity (Pierantoni et al., 2024; van Zijl et al., 2011)."
    },
    {
      "title": "Comparative Analysis of Neoplasms",
      "body_markdown": ""
    },
    {
      "title": "Clinical Significance of Biological Divergence",
      "body_markdown": "The biological divergence between benign and malignant tumors dictates the selection of treatment modalities. Benign tumors often allow for watchful waiting or simple surgical excision due to their circumscribed nature. In contrast, the infiltrative and metastatic capacity of malignant tumors necessitates aggressive, multi-modal management. The choice between local control (surgery, radiotherapy) and systemic intervention (chemotherapy, immunotherapy) is governed by the risk of subclinical dissemination, which remains the primary driver of cancer-related mortality (van Zijl et al., 2011).\n\nWhile classification provides the \"what\" of a tumor, the mechanistic \"how\" is determined by the specific genetic and epigenetic drivers that fuel the transition from homeostasis to malignancy.\n\n--------------------------------------------------------------------------------"
    },
    {
      "title": "2. Carcinogenesis: The Molecular Logic of Transformation",
      "body_markdown": ""
    },
    {
      "title": "Multistep Mutation Theory",
      "body_markdown": "Carcinogenesis is governed by the , which posits that the transition from a benign polyp to an invasive carcinoma is a cumulative process of genetic and epigenetic insults. In colorectal cancer (CRC), this is visualized as a predictable progression where each hit confers a selective phenotypic advantage. This transition is not merely about growth; it is about the systematic dismantling of cellular checks and balances (Pierantoni et al., 2024)."
    },
    {
      "title": "Genetic Drivers of Transformation",
      "body_markdown": ""
    },
    {
      "title": "Oncogenes:Ras/MAPK cascadeRAF, PI3K, MAPK, and RALGDS",
      "body_markdown": "- These genes sustain proliferative signaling. Mutations in KRAS or BRAF trigger the . Crucially, this involves signaling through , which collectively drive autonomous growth and resistance to apoptosis (Pierantoni et al., 2024)."
    },
    {
      "title": "Tumor Suppressor Genes:Chromosomal Instability (CIN) pathwayreduction in beta-catenin degradation",
      "body_markdown": "- The \"Two-Hit\" hypothesis typically governs these loss-of-function events. In the , the loss of APC is a hallmark. Mechanistically, APC mutation causes a , allowing beta-catenin to accumulate and translocate to the nucleus, where it activates pro-proliferative gene programs. Subsequent loss of TP53 eliminates the cell's ability to trigger senescence or apoptosis in response to DNA damage (Pierantoni et al., 2024)."
    },
    {
      "title": "DNA Repair Genes:Microsatellite Instability (MSI) pathway",
      "body_markdown": "- The  arises from a defective DNA mismatch repair (MMR) system, often via the silencing of MLH1 or MSH2."
    },
    {
      "title": "Clinical Impact: The \"So What?\" LayerMSI-H (MSI-High)numerous neoantigensPD-1 inhibition",
      "body_markdown": "The molecular pathway of a tumor dictates its clinical management. CIN-driven tumors are characterized by gross structural anomalies, while  tumors exhibit a high mutational load. This high mutational burden is clinically significant because it results in the production of . These neoantigens make MSI-H tumors highly susceptible to  (e.g., pembrolizumab), as the immune system can more readily recognize the \"non-self\" nature of the tumor (Pierantoni et al., 2024; Hanahan, 2022)."
    },
    {
      "title": "phenotypic plasticity",
      "body_markdown": "These genetic alterations confer the  required for the tumor to survive in hostile environments and adopt new identities during progression.\n\n--------------------------------------------------------------------------------"
    },
    {
      "title": "3. Phenotypic Plasticity and the Hallmarks of Cancer",
      "body_markdown": ""
    },
    {
      "title": "Phenotypic Plasticitynonmutational epigenetic reprogramming",
      "body_markdown": "A revolutionary dimension of the Hallmarks of Cancer is , which describes the ability of cancer cells to escape terminal differentiation and adopt progenitor-like states. Crucially, this plasticity often occurs independently of genetic mutation, relying instead on  to alter cellular identity (Hanahan, 2022; CST Blog, 2022)."
    },
    {
      "title": "Mechanisms of Plasticity",
      "body_markdown": ""
    },
    {
      "title": "Dedifferentiation:Epithelial-Mesenchymal Transition (EMT)\"Cadherin Switch\"Snail, Slug, ZEB1, and Twist",
      "body_markdown": "- Mature cells revert to a progenitor state. A primary model is the , where epithelial cells lose apical-basal polarity and adopt a motile phenotype. This is driven by the  (loss of E-cadherin, gain of N-cadherin) and a network of transcription factors:  (CST Blog, 2022)."
    },
    {
      "title": "Blocked Differentiation:Acute Myeloid Leukemia (AML)CD33Myeloperoxidase (MPO)",
      "body_markdown": "- Progenitor cells are prevented from reaching a post-proliferative state. In , cells retain high proliferative capacity. Pathologists investigate these blocked progenitors using specific biomarkers:  and  (CST Blog, 2022)."
    },
    {
      "title": "Transdifferentiation:Barrett’s EsophagusCDX2, MUC2CK7/CK20",
      "body_markdown": "- Cells transform into a different differentiated lineage. In , squamous cells transform into intestinal-like columnar cells. This is confirmed by the presence of intestinal markers () and a shift in keratins () (CST Blog, 2022)."
    },
    {
      "title": "Clinical Strategy: Differentiation TherapyDifferentiation Therapydisrupt retinoic acid (RA) signaling",
      "body_markdown": "Understanding \"Blocked Differentiation\" has permitted the development of . In Acute Promyelocytic Leukemia (APL), chromosomal translocations , halting myeloid maturation. By pharmacologically restoring RA signaling, clinicians can force leukemic cells to complete their differentiation into post-proliferative states, effectively inducing remission without cytotoxic destruction (CST Blog, 2022).\n\nThis cellular agility is the prerequisite for the physical act of invasion and the navigation of the lethal metastatic cascade.\n\n--------------------------------------------------------------------------------"
    },
    {
      "title": "4. Mechanisms of Tumor Progression: Invasion and the Metastatic Cascade",
      "body_markdown": ""
    },
    {
      "title": "Metastatic Cascade",
      "body_markdown": "The  is a multi-step process that is statistically inefficient—fewer than 0.1% of disseminated cells successfully colonize—yet it remains the primary cause of cancer death. To succeed, tumor cells must overcome physical, physiological, and immunological barriers (van Zijl et al., 2011)."
    },
    {
      "title": "Modes of Invasion and Movement",
      "body_markdown": ""
    },
    {
      "title": "Collective Invasion:\"tip cells\"",
      "body_markdown": "- Cells move as coordinated clusters. Leading  drive the process through focal adhesions and ECM rearrangement."
    },
    {
      "title": "Mesenchymal-to-Amoeboid Transition (MAT):Amoeboid movementEphA2 kinase, p27 kip1, and p53",
      "body_markdown": "- Mesenchymal movement is protease-dependent and slow. However, when proteases are inhibited, cells switch to —a high-velocity, protease-independent strategy where cells squeeze through ECM gaps. This transition is regulated by  (van Zijl et al., 2011)."
    },
    {
      "title": "Molecular Mechanism of IntravasationALOX12/1512(S)-HETEtransiently reduces VE-cadherin expressioncircular defects",
      "body_markdown": "Tumor cells actively create \"gates\" for transmigration. Mammary carcinoma cells use  to metabolize arachidonic acid into . This metabolite  in endothelial cells, creating  through which the tumor cells can enter the vasculature (van Zijl et al., 2011)."
    },
    {
      "title": "The Role of the MicroenvironmentCancer-Associated Fibroblasts (CAFs)CXCL12/CXCR4 loopIntegrins",
      "body_markdown": "Tumor progression is a heterotypic process.  communicate with cancer cells via a , facilitating migration. Simultaneously,  (e.g., \\alpha V\\beta 3) localize Matrix Metalloproteinases (MMPs) to the leading edge to degrade the ECM (van Zijl et al., 2011; Koistinen & Heino, 2000-2013). The clinical failure of MMP inhibitors is largely due to the MAT exit strategy, highlighting the need for multi-modal therapy.\n\n--------------------------------------------------------------------------------"
    },
    {
      "title": "5. Clinical Evaluation: Grading, Staging, and Screening Principles",
      "body_markdown": "Pathological grading and clinical staging translate molecular complexity into a standardized roadmap for management. While grading assesses the tumor's \"personality,\" staging determines its \"territory.\""
    },
    {
      "title": "Grading and Staging Defined",
      "body_markdown": ""
    },
    {
      "title": "Grading:Gleason score",
      "body_markdown": "- A measure of cytological differentiation (e.g., the )."
    },
    {
      "title": "Staging:TNM System",
      "body_markdown": "- Defined by the  (Tumor size, Node involvement, Metastasis)."
    },
    {
      "title": "Metastatic Models: Linear vs. ParallelLinear Progression ModelParallel Progression ModelERBB2 (HER2/neu) mutant breast cancerprior to morphological invasion",
      "body_markdown": "The  suggests dissemination occurs late, after the primary tumor has extensively evolved. Conversely, the  claims early dissemination. A classic example of the latter is , where dissemination often occurs  of the primary tumor (van Zijl et al., 2011)."
    },
    {
      "title": "The \"Seed and Soil\" Theory: Mechanistic \"Why\"bone matrix stores TGF-betaRANKLosteolytic cycle",
      "body_markdown": "Stephen Paget’s theory explains organ-specific metastasis. For instance, breast cancer preferentially colonizes bone because the . When tumor cells invade, the release of TGF-beta stimulates the production of parathyroid hormone-related protein and , which mobilizes osteoclasts. This creates an  that provides a fertile environment for tumor growth (van Zijl et al., 2011). This mechanistic understanding dictates that screening must be targeted toward the specific \"soils\" most compatible with a given \"seed.\"\n\nThe future of oncology lies in merging these established clinical frameworks with the molecular pathways of phenotypic plasticity and genetic instability to create a personalized approach to care.\n\n--------------------------------------------------------------------------------"
    },
    {
      "title": "6. Works Cited",
      "body_markdown": "Cell Signaling Technology. (2022). Hallmarks of cancer: Unlocking phenotypic plasticity - CST blog. https://www.cellsignal.com/blog/hallmarks-of-cancer-unlocking-phenotypic-plasticity\n\nHanahan, D. (2022). Hallmarks of cancer: New dimensions. Cancer Discovery, 12(1), 31-46. https://doi.org/10.1158/2159-8290.CD-21-1059\n\nHanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. Cell, 144(5), 646-674. https://doi.org/10.1016/j.cell.2011.02.013\n\nKoistinen, P., & Heino, J. (2000-2013). Integrins in cancer cell invasion. Madame Curie Bioscience Database. Landes Bioscience. https://www.ncbi.nlm.nih.gov/books/NBK6070/\n\nPierantoni, C., Cosentino, L., & Ricciardiello, L. (2024). Molecular pathways of colorectal cancer development: Mechanisms of action and evolution of main systemic therapy compounds. Digestive Diseases, 42(4), 319–324. https://doi.org/10.1159/000538511\n\nvan Zijl, F., Krupitza, G., & Mikulits, W. (2011). Initial steps of metastasis: Cell invasion and endothelial transmigration. Mutation Research, 728(1-2), 23–34. https://doi.org/10.1016/j.mrrev.2011.05.002"
    }
  ]
}